Scientific Reference
TB-500
Evidence profile: Human trials studied full-length thymosin beta-4, not the TB-500 fragment
TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) corresponding to the active actin-binding region (positions 17-23) of thymosin beta-4. Originally developed for veterinary use, this fragment retains tissue repair and anti-inflammatory properties while being more stable than the full peptide. TB-500 regulates actin dynamics, promotes cell migration, enhances angiogenesis, and reduces inflammation, contributing to accelerated tissue repair across multiple systems. Its systemic distribution enables whole-body regenerative support rather than localized effects alone.
Published Research
Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis
Sosne G et al. · International immunopharmacology · 2023 · Clinical
PMID 37018981 — View on PubMedRGN-259 neurotrophic keratopathy phase III
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
Sosne G et al. · International journal of molecular sciences · 2022 · Clinical
PMID 36613994 — View on PubMedThe effect of thymosin treatment of venous ulcers
Guarnera G et al. · Annals of the New York Academy of Sciences · 2010 · Clinical
PMID 20536470 — View on PubMedA randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers
Ruff D et al. · Annals of the New York Academy of Sciences · 2010 · Clinical
PMID 20536472 — View on PubMedSimultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
Rahaman KA et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024 · Preclinical
PMID 38382158 — View on PubMedSynthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
Esposito S et al. · Drug testing and analysis · 2012 · Preclinical
PMID 22962027 — View on PubMed